We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Five Deaths Draw Partial Clinical Hold for Ovarian Cancer Trials
Five Deaths Draw Partial Clinical Hold for Ovarian Cancer Trials
Two clinical trials of Mersana Therapeutics’ ovarian cancer drug UpRi (upifitamab rilsodotin) are on a partial clinical hold from the FDA because of five deaths linked to serious bleeding.
